Chugai Pharmaceuticals (4519-TO)

FierceBiotech  Jul 21  Comment 
Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai ntaylor Thu, 07/21/2016 - 08:39  Dec 14  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. said Genentech Inc., a member of the Roche Group, obtained approval from the U.S. Food and Drug Administration, for the anti-cancer agent, alectinib hydrochloride or Alecensa for the...
Benzinga  Oct 21  Comment 
Athersys, Inc. ("Athersys") (NASDAQ: ATHX) announced today that Athersys and Chugai Pharmaceutical Co., Ltd. ("Chugai") have ended the license agreement between them for the exclusive development and commercialization of MultiStem® cell therapy...
FierceBiotech  Mar 2  Comment 
Cleveland-based Athersys is pocketing a $10 million upfront payment from Chugai in exchange for licensing rights to the biotech's stem cell treatment for repairing stroke damage. The Japanese pharma company, which has close relations with Roche,...  Mar 2  Comment 
CLEVELAND, Ohio (TheStreet) -- Athersys found a partner willing to help develop its off-the-shelf stem cell therapy for stroke in Japan. The timing of the new partnership with Japanese drug maker Chugai is a bit odd, however, coming just one...
GenEng News  Mar 2  Comment 
Athersys will co-develop and co-commercialize its MultiStem® cell therapy for ischemic stroke in Japan by bringing in a partner, Chugai Pharmaceutical, in a deal that could net Athersys up to $205 million-plus. MultiStem is under Phase II...

You may also be interested in articles related to Chugai Pharmaceuticals (4519-TO):
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki